| filibuvir (PF-00868554) / Pfizer |
NCT00445315: A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients |
|
|
| Completed | 1 | 32 | Europe | PF-00868554, Placebo | Pfizer | Hepatitis C | 06/08 | 06/08 | | |
NCT00651027: Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554 |
|
|
| Completed | 1 | 24 | US | PF-868554 | Pfizer | HEPATITIS C (HCV) | 09/08 | 09/08 | | |
NCT00671671: Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus. |
|
|
| Completed | 1 | 20 | US | Small Molecule Agent (PF-868554) | Pfizer | Hepatitis, Chronic, Hepatitis C Virus | 12/08 | 12/08 | | |
NCT00861458: Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State |
|
|
| Completed | 1 | 14 | Europe | Pharmacokinetics, pharmacokintics | Pfizer | Hepatitis C Virus | 06/09 | 06/09 | | |
NCT00918476: Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol) |
|
|
| Completed | 1 | 14 | Europe | filibuvir + Oral Contraceptives | Pfizer | Hepatitis C | 02/11 | 02/11 | | |
NCT01210404: Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance |
|
|
| Completed | 1 | 12 | US | filibuvir | Pfizer | Chronic Hepatitis C | 05/11 | 06/11 | | |
